Investors run financial due diligence. They look at your revenue quality, your margins, your churn, your customer concentration. They build their own model, stress-test your projections, and apply discounts to anything that doesn't hold up.
Almost nobody runs commercial due diligence on their own company before the process starts.
That gap is expensive. Not because founders are unprepared. Because the questions investors ask in diligence are different from the questions founders prepare for in the pitch. And by the time those questions surface, the leverage is already gone.
What is GTM due diligence?
GTM due diligence is a structured commercial assessment of how your go-to-market engine actually works and what is limiting it.
It is not a pitch review. It is not a financial audit. It is a diagnostic that looks at the commercial mechanics of your business and answers the questions a sophisticated investor will eventually ask — before they ask them.
The questions it answers include:
- How repeatable is your revenue generation and does it depend on you personally to close?
- Who are your best customers, what triggered them to buy, and how accurately does your current ICP reflect that?
- Where in the funnel does the commercial motion break and what is causing it?
- What is your net revenue retention and what does it tell you about customer fit?
- How accurately does your pipeline predict your close rate and your revenue?
- What is your customer concentration and what does that mean for the quality of your ARR?
These are not vanity metrics. They are the commercial signals that determine whether an investor is underwriting a business with a real engine or one that is growing because the founder is exceptional at selling.
The core distinction: Financial due diligence tells investors what you have built. GTM due diligence tells them whether what you have built can scale beyond you. These are different stories about the same company, and investors know the difference.
Why does it matter before you raise?
Every commercial gap an investor finds in diligence becomes a negotiating point that belongs to them. Every gap you find first is one you control. You can address it, disclose it with context, or frame it as a known constraint with a clear path to resolution.
The founder who walks into a Series A process having already run their own commercial diagnostic is in a categorically different position from the one who encounters these findings for the first time across the table from an investor.
The four commercial signals investors actually look at
1. Revenue quality
Investors separate recurring revenue from one-time revenue before they apply a multiple. Services revenue bundled into ARR inflates the number they use to value the business and they will strip it out. If you are reporting $2M ARR and $400K of that is professional services, you are being valued on $1.6M of recurring revenue. This adjustment happens silently unless you surface it first.
2. Customer concentration
If your top three accounts represent more than 40% of ARR, investors are pricing the risk that one of them leaves post-raise. This is not a conversation they announce. It appears in the term sheet as a valuation discount or a condition. Knowing your concentration number before they calculate it allows you to either address it in the 90 days before the raise or prepare the narrative that prevents a silent discount.
3. Forecast accuracy
Four quarters of forecasts averaging 35% variance tells an investor your pipeline is not predictable. They build their own forward model and apply a credibility discount to your projections. This does not show up as a question. It shows up in the offer. One quarter of meaningfully improved accuracy before the raise starts directly affects how much they trust your numbers.
4. Founder dependency
Growth stage investors are underwriting whether capital can accelerate the commercial motion. If you close more than 50% of deals personally, the motion does not scale with investment. It scales with your personal capacity, which is already at its limit. This is the signal that most founders are unaware of and most investors are looking for.
When should you run GTM due diligence?
The right time is 60 to 90 days before you begin investor conversations. Not during. Not after the first meeting. Before.
That timing gives you enough runway to address the gaps that are addressable, build the narrative for the ones that are not, and walk into the process with a clear and honest picture of your own commercial story.
The founder who runs this diagnostic before the process starts does not necessarily have a perfect commercial story. They have a controlled one. And that distinction is worth more than any pitch deck.
The practical reality: Most investors will find what is there regardless of what you show them. The question is whether they find it before or after the term sheet, and whether you are the one surfacing it with context or they are the one surfacing it as a negotiating lever.
What GTM due diligence is not
It is not advice about what to build next. It is not a strategy session. It is not a retainer engagement that asks you to commit to six months of work before you know what the problem is.
GTM due diligence is a diagnostic. Its job is to show you what is actually in your commercial engine, not to tell you what should be there. The action is yours. The visibility is what the diagnostic provides.
Run your commercial diagnostic before your next raise.
The Revenue Due Diligence assessment maps the commercial signals investors will examine and tells you what they find before you walk into the room.
See what the assessment covers →